IRIDEX Corporation reported a notable turnaround in its financial performance for 2025, achieving full-year revenue of $52.7 million, an 8% increase driven by strong sales across its glaucoma and retina product lines. The fourth quarter alone saw a 16% revenue growth, marking the highest quarterly growth rate of the year. This growth was complemented by a significant reduction in operating expenses, which fell by 22%, and a positive adjusted EBITDA of $817,000, the first in recent history, indicating a shift towards sustainable profitability.
The company’s strategic initiatives, including a transition to third-party manufacturing and operational streamlining, are expected to enhance gross margins moving forward. However, management has noted challenges, particularly in the Middle East due to regional conflicts and ongoing macroeconomic volatility affecting sales in Asia. These factors have led to cautious revenue guidance for 2026, projecting growth of only 1% to 5% after excluding Middle Eastern sales.
Market professionals should note that while IRIDEX is on a path to improved financial health, geopolitical risks and manufacturing cost pressures remain critical factors that could impact future performance.
Source: fool.com